The arithmetic of shareholder returns at Novo Nordisk tells a story of patience under pressure. The Danish drugmaker has plowed 8.08 billion Danish kroner into buying back its own B-shares since February, snapping up 28.88 million shares at an average price of 279.80 kroner. That leaves the company holding 42.92 million treasury shares, roughly one percent of its share capital — a modest dent in a buyback program with a ceiling of 11.2 billion kroner that runs until early February 2027.
The capital returns don’t stop there. Monday brought a cash dividend of $0.579 per share, with the ex-date now passed. Taken together, the payout and the buyback signal that management intends to keep funneling cash back to shareholders even as the stock wallows well below its highs — a deliberate counterweight to the operational headwinds piling up in the obesity market.
Investors, however, are proving hard to win over. The shares changed hands at €39.60 on Tuesday, up 1.9 percent on the day, but that bounce does little to repair a bruised chart. The stock sits 28 percent below its 52-week peak of €54.86, touched back in January, and has shed 10 percent since the start of the year. Over twelve months, the decline stretches to 14 percent. Technical indicators reinforce the gloom: the relative strength index reads 38.5, putting the shares in oversold territory, yet the price still trails both the 50-day moving average of €41.44 and the 200-day average of €40.26.
Chief executive Mike Doustdar has a straightforward retort to the skeptics: they’re underestimating demand for differentiated obesity treatments. In a Reuters interview last Thursday, he argued that new options such as oral formulations will stop the market from collapsing into a two-horse race with Eli Lilly. The company is pressing ahead with plans to launch CagriSema next year, even though trial data on weight loss lagged behind Lilly’s Zepbound. Doustdar’s bet is on portfolio breadth rather than a single flagship product.
That strategy has already shown up in the numbers. Half-year results released about two weeks ago delivered adjusted operating profit of 33.389 billion kroner, prompting management to lift its full-year guidance for both adjusted sales growth and operating profit. The initial market response was a 1.1 percent gain — until disappointing study data knocked the stock down 2.7 percent shortly after. The buyback, last reported just over three weeks ago, hasn’t steadied the ship either; the shares have lost 14.1 percent since that update.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Doustdar has also signaled restraint on the deal-making front. Earlier this month he told the Wall Street Journal he remains open to smaller acquisitions but rules out transformative takeovers — a clear preference for organic growth over blockbuster M&A.
On the legal side, the company has banked two wins. A US federal judge dismissed an antitrust suit filed by a compounding manufacturer that accused Novo Nordisk and Eli Lilly of blocking access to personalized GLP-1 products. In the Netherlands, a court in The Hague issued a preliminary injunction against Ceban Ziekenhuisfarmacie B.V. over a compounded semaglutide nasal spray, finding the company had infringed Novo Nordisk’s supplementary protection certificate. Ceban must remove product listings, disclose supply-chain details, and cover the drugmaker’s legal costs. With demand for GLP-1 treatments running hot, more such battles with copycat providers look likely.
The company is also leaning into technology, having struck a partnership with Amazon Web Services to accelerate drug discovery using artificial intelligence.
All eyes now turn to September 21, when Novo Nordisk hosts its Capital Markets Day. Management is expected to spotlight early- and mid-stage pipeline projects, including next-generation amylin therapies and tri-agonists. Quarterly results for the first three quarters of 2026 follow on November 4. Until then, the combination of dividends, buybacks, and patent defense is what holds the story together — even as the market waits for Doustdar’s confidence in demand to show up in actual sales figures.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 18 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 18.
Novo Nordisk: Buy or sell? Read more here...
